Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.50 |
| ▸ | ACE | P12821 | 5/20 | 0.50 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.48 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20583647 | 1.00 | MME (0.50) | MMEACEGPR88HDAC1HDAC6 | |
| SCHEMBL20583645 | 1.00 | MME (0.50) | MMEACEGPR88HDAC1HDAC6 | |
| SCHEMBL20583644 | 1.00 | MME (0.50) | MMEACEGPR88HDAC1HDAC6 | |
| SCHEMBL3044859 | 0.91 | ALDH1A1 (0.52) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL29077049 | 0.91 | ALDH1A1 (0.52) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL1531738 | 0.91 | ALDH1A1 (0.52) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL1531741 | 0.91 | ALDH1A1 (0.52) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL13386099 | 0.91 | ALDH1A1 (0.52) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL1531689 | 0.90 | ALDH1A1 (0.51) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL1531688 | 0.90 | ALDH1A1 (0.51) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532673-A2 | Tubulysine derivatives | R & D Biopharmaceuticals Gmbh (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2008138561-A1 | TUBULYSINE DERIVATIVES | R & D BIOPHARMACEUTICALS GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | GLS, TPX2, HKDC1 | MME 349/4885ACE 2670/4885GPR88 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.